Cyteir Therapeutics Inc
NASDAQ:CYT
Intrinsic Value
Cyteir Therapeutics, Inc. engages in the development of novel therapeutics and deoxyribonucleic acid repair and synthetic lethal therapies. [ Read More ]
The intrinsic value of one CYT stock under the Base Case scenario is 4.08 USD. Compared to the current market price of 3.01 USD, Cyteir Therapeutics Inc is Undervalued by 26%.
Valuation Backtest
Cyteir Therapeutics Inc
Run backtest to discover the historical profit from buying and selling CYT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cyteir Therapeutics Inc
Current Assets | 130.6m |
Cash & Short-Term Investments | 129.2m |
Other Current Assets | 1.4m |
Non-Current Assets | 400k |
PP&E | 100k |
Other Non-Current Assets | 300k |
Current Liabilities | 6m |
Accounts Payable | 500k |
Accrued Liabilities | 5.5m |
Earnings Waterfall
Cyteir Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-34m
USD
|
Operating Income
|
-34m
USD
|
Other Expenses
|
740k
USD
|
Net Income
|
-33.2m
USD
|
Free Cash Flow Analysis
Cyteir Therapeutics Inc
What is Free Cash Flow?
CYT Profitability Score
Profitability Due Diligence
Cyteir Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Cyteir Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
CYT Solvency Score
Solvency Due Diligence
Cyteir Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Cyteir Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYT Price Targets Summary
Cyteir Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CYT is 3 USD .
Ownership
CYT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CYT Price
Cyteir Therapeutics Inc
Average Annual Return | -61.95% |
Standard Deviation of Annual Returns | 31.61% |
Max Drawdown | -95% |
Market Capitalization | 108.7m USD |
Shares Outstanding | 36 030 500 |
Percentage of Shares Shorted | 1.01% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cyteir Therapeutics, Inc. engages in the development of novel therapeutics and deoxyribonucleic acid repair and synthetic lethal therapies. The company is headquartered in Lexington, Massachusetts and currently employs 40 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing and commercializing precision oncology medicines that inhibit deoxyribonucleic acid (DNA) damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. The firm's pipeline includes CYT-0851 and CYT-1853. Its lead program, CYT-0851, is an oral, once-daily, small molecule inhibitor of RAD51-mediated homologous recombination (HR), a DNA repair pathway critical for the survival of some cancers in Phase II. The firm is developing CYT-1853 as an inhibitor of RAD51-mediated HR.
Contact
IPO
Employees
Officers
The intrinsic value of one CYT stock under the Base Case scenario is 4.08 USD.
Compared to the current market price of 3.01 USD, Cyteir Therapeutics Inc is Undervalued by 26%.